[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipid-rich-atherosclerosis-of-coronary-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipid-rich-atherosclerosis-of-coronary-artery":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100601244","drug-eluting-balloon-treatment-vs-guideline-directed-medical-therapy-for-the-treatment-of-lipid-rich-plaques-100601244",false,"NCT07107971","Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques","Drug-Eluting Balloon Treatment Versus Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques: A Randomized Controlled Trial","DELETE-LRP","Inclusion Criteria:\n\n* Presenting with acute coronary syndrome (ACS);\n* Successful PCI of a native coronary artery or major side branch;\n* At least 2 native coronary arteries are accessible for invasive coronary imaging; i.e. not totally occluded and \\>2 mm and \\\u003C6 mm reference vessel diameter.\n\nExclusion Criteria:\n\n* Hemodynamically unstable (presence of cardiogenic shock, need for intubation, need for inotropes);\n* Known hypersensitivity to paclitaxel;\n* Procedural complications of the index PCI;\n* Known renal insufficiency, i.e. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2;\n* Hypersensitivity or allergy to contrast with inability to administer steroid and antihistamine premedication;\n* Presence of a comorbid condition with a life expectancy of less than one year;\n* Body weight \\>250 kg;\n* Subject belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to find out whether treating vulnerable plaques in the coronary arteries with a drug-coated balloon can make them less dangerous than using standard medication alone. The study includes adults with acute coronary syndrome (a type of heart problem caused by reduced blood flow in the coronary arteries).\n\nThe main questions the study aims to answer are:\n\n* Does the drug-coated balloon reduce the amount of fat inside the plaque more than medication alone?\n* Is this treatment safe for patients?\n\nParticipants will:\n\n* Undergo imaging of their coronary arteries during their planned heart procedure (PCI)\n* Be randomly assigned to receive either a drug-coated balloon treatment or no extra treatment\n* Undergo a heart scan (CT scan of the coronary arteries) within 2 weeks and again around 9 months after the procedure.\n* Undergo a second heart catherization 9 months later to examine changes in the plaque.",[27,28,29,30,31,32,33],"Coronary Artery Disease","Atheroscleroses","Cardiovascular Disease","Vulnerable Coronary Plaques","Vulnerable Plaque","Lipid-Rich Atherosclerosis of Coronary Artery","Acute Coronary Syndromes (ACS)",[35,36,37,38,39,40,41,42,43],"Lipid-rich plaque","Vulnerable plaque","Near-infrared spectroscopy","Drug-coated balloon","Drug-eluting balloon","Paclitaxel-eluting balloon","Intravascular Ultrasound","Coronary computed tomography angiography","AI-QCT","RECRUITING","2026-01-14",{"date":47,"type":48},"2026-01-15","ACTUAL",{"date":50,"type":48},"2025-11-04",{"date":52,"type":21},"2033-01",{"name":54,"class":55},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100428831","reassure-nirs-registry-100428831","NCT04864171","REASSURE-NIRS Registry","REvelation of PAthophySiological PhenotypeS of VUlneRable Lipid-Rich PlaquE on Near-InfraRed Spectroscopy: REASSURE-NIRS","REASSURENIRS","Inclusion Criteria:\n\npatients with coronary artery disease clinical indication for coronary angiography and\u002For percutaneous coronary intervention visualization of coronary lesions with NIRS\n\nExclusion Criteria:\n\npoor quality of NIRS images","20 Years","95 Years",{"count":68,"type":21},2000,"5 Years","OBSERVATIONAL","RESSURE-NIRS registry is designed to investigate clinical and pathophysiological characteristics of NIRS-derived lipid-rich plaque in patients with coronary artery disease. This is an on-going multi-center prospective registry in Japan.",[32],[74,75,76,77],"near-infrared spectroscopy","lipid-rich plaque","coronary artery disease","intravascular imaging","2025-08-12",{"date":80,"type":48},"2025-08-15",{"date":82,"type":48},"2018-10-09",{"date":84,"type":21},"2030-03-31",{"name":86,"class":55},"National Cerebral and Cardiovascular Center, Japan"]